3-24 | A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and more patient data was extremely unlikely to change the trial’s outcome.

Johnson & Johnson TB drug price reduction is important step, and governments need to urgently scale up better treatment

7-6 | 120,707 people signed petitions urging the corporation to drop the price.

Responding to COVID-19 in conflict-affected eastern Ukraine

5-9 | The only European country facing an armed conflict, Ukraine's healthcare system was already under great strain, especially in the east where sporadic hostilities have left many struggling to access healthcare. The spread of COVID-19 threatens to further overwhelm the country's healthcare capacity.

HIV project in Eshowe, South Africa reaches 90-90-90 target one year ahead of 2020 deadline

6-12 | Médecins Sans Frontières (MSF) released findings from a follow-up survey of its community-based HIV/TB project in Eshowe, KwaZulu Natal.

MSF warns high prices of tuberculosis drugs restrict people´s access to best drug-resistant TB treatment

10-20 | ©MSF Calls on US pharma corporation Johnson & Johnson to cut key TB drug price in half People with drug-resistant tuberculosis (DR-TB) continue to be deprived of today’s best-possible treatment